EP Patent

EP3810623A1 — A novel process for the preparation of sglt-2 inhibitors

Assigned to Pharmathen SA · Expires 2021-04-28 · 5y expired

What this patent protects

The present invention relates to a novel process for the preparation of SGLT-2 inhibitors via addition of a hydroxymethylene group in an open chain intermediate, readily accessible from D-glucose.

USPTO Abstract

The present invention relates to a novel process for the preparation of SGLT-2 inhibitors via addition of a hydroxymethylene group in an open chain intermediate, readily accessible from D-glucose.

Drugs covered by this patent

Patent Metadata

Patent number
EP3810623A1
Jurisdiction
EP
Classification
—
Expires
2021-04-28
Drug substance claim
No
Drug product claim
No
Assignee
Pharmathen SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.